nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Coordination abnormal—Epirubicin—sarcoma	0.00554	0.00554	CcSEcCtD
Apraclonidine—Lacrimation increased—Doxorubicin—sarcoma	0.00546	0.00546	CcSEcCtD
Apraclonidine—Angiopathy—Vincristine—sarcoma	0.00545	0.00545	CcSEcCtD
Apraclonidine—Ill-defined disorder—Dactinomycin—sarcoma	0.00543	0.00543	CcSEcCtD
Apraclonidine—Infestation NOS—Etoposide—sarcoma	0.00542	0.00542	CcSEcCtD
Apraclonidine—Infestation—Etoposide—sarcoma	0.00542	0.00542	CcSEcCtD
Apraclonidine—Mediastinal disorder—Vincristine—sarcoma	0.00542	0.00542	CcSEcCtD
Apraclonidine—Dermatitis contact—Epirubicin—sarcoma	0.00537	0.00537	CcSEcCtD
Apraclonidine—Malaise—Dactinomycin—sarcoma	0.00528	0.00528	CcSEcCtD
Apraclonidine—Mental disorder—Vincristine—sarcoma	0.00527	0.00527	CcSEcCtD
Apraclonidine—Arrhythmia—Mitoxantrone—sarcoma	0.00523	0.00523	CcSEcCtD
Apraclonidine—Inflammation—Doxorubicin—sarcoma	0.00519	0.00519	CcSEcCtD
Apraclonidine—Coordination abnormal—Doxorubicin—sarcoma	0.00512	0.00512	CcSEcCtD
Apraclonidine—Erythema—Mitoxantrone—sarcoma	0.0051	0.0051	CcSEcCtD
Apraclonidine—Myalgia—Thiotepa—sarcoma	0.00502	0.00502	CcSEcCtD
Apraclonidine—Dry eye—Epirubicin—sarcoma	0.00502	0.00502	CcSEcCtD
Apraclonidine—Dysgeusia—Mitoxantrone—sarcoma	0.00499	0.00499	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00499	0.00499	CcSEcCtD
Apraclonidine—Myalgia—Dactinomycin—sarcoma	0.00499	0.00499	CcSEcCtD
Apraclonidine—Dermatitis contact—Doxorubicin—sarcoma	0.00497	0.00497	CcSEcCtD
Apraclonidine—Discomfort—Dactinomycin—sarcoma	0.00493	0.00493	CcSEcCtD
Apraclonidine—Vision blurred—Mitoxantrone—sarcoma	0.0048	0.0048	CcSEcCtD
Apraclonidine—Infection—Thiotepa—sarcoma	0.00478	0.00478	CcSEcCtD
Apraclonidine—Oedema—Dactinomycin—sarcoma	0.00478	0.00478	CcSEcCtD
Apraclonidine—Infection—Dactinomycin—sarcoma	0.00475	0.00475	CcSEcCtD
Apraclonidine—Abnormal vision—Epirubicin—sarcoma	0.00474	0.00474	CcSEcCtD
Apraclonidine—Ill-defined disorder—Mitoxantrone—sarcoma	0.00473	0.00473	CcSEcCtD
Apraclonidine—Nervous system disorder—Thiotepa—sarcoma	0.00472	0.00472	CcSEcCtD
Apraclonidine—Skin disorder—Thiotepa—sarcoma	0.00468	0.00468	CcSEcCtD
Apraclonidine—Dry eye—Doxorubicin—sarcoma	0.00465	0.00465	CcSEcCtD
Apraclonidine—Malaise—Mitoxantrone—sarcoma	0.0046	0.0046	CcSEcCtD
Apraclonidine—Eye disorder—Etoposide—sarcoma	0.00455	0.00455	CcSEcCtD
Apraclonidine—Myalgia—Vincristine—sarcoma	0.00446	0.00446	CcSEcCtD
Apraclonidine—Angiopathy—Etoposide—sarcoma	0.00442	0.00442	CcSEcCtD
Apraclonidine—Mediastinal disorder—Etoposide—sarcoma	0.00439	0.00439	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00439	0.00439	CcSEcCtD
Apraclonidine—Abnormal vision—Doxorubicin—sarcoma	0.00439	0.00439	CcSEcCtD
Apraclonidine—Eye pain—Epirubicin—sarcoma	0.00437	0.00437	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00436	0.00436	CcSEcCtD
Apraclonidine—Chest pain—Mitoxantrone—sarcoma	0.00434	0.00434	CcSEcCtD
Apraclonidine—Myalgia—Mitoxantrone—sarcoma	0.00434	0.00434	CcSEcCtD
Apraclonidine—Paraesthesia—Thiotepa—sarcoma	0.00432	0.00432	CcSEcCtD
Apraclonidine—Discomfort—Mitoxantrone—sarcoma	0.00429	0.00429	CcSEcCtD
Apraclonidine—Somnolence—Thiotepa—sarcoma	0.00428	0.00428	CcSEcCtD
Apraclonidine—Oedema—Vincristine—sarcoma	0.00427	0.00427	CcSEcCtD
Apraclonidine—Infection—Vincristine—sarcoma	0.00424	0.00424	CcSEcCtD
Apraclonidine—Nervous system disorder—Vincristine—sarcoma	0.00419	0.00419	CcSEcCtD
Apraclonidine—Oedema—Mitoxantrone—sarcoma	0.00416	0.00416	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Thiotepa—sarcoma	0.00416	0.00416	CcSEcCtD
Apraclonidine—Fatigue—Thiotepa—sarcoma	0.00415	0.00415	CcSEcCtD
Apraclonidine—Dysgeusia—Etoposide—sarcoma	0.00415	0.00415	CcSEcCtD
Apraclonidine—Infection—Mitoxantrone—sarcoma	0.00413	0.00413	CcSEcCtD
Apraclonidine—Fatigue—Dactinomycin—sarcoma	0.00412	0.00412	CcSEcCtD
Apraclonidine—Pain—Thiotepa—sarcoma	0.00412	0.00412	CcSEcCtD
Apraclonidine—Constipation—Thiotepa—sarcoma	0.00412	0.00412	CcSEcCtD
Apraclonidine—Pain—Dactinomycin—sarcoma	0.00409	0.00409	CcSEcCtD
Apraclonidine—Eye pain—Doxorubicin—sarcoma	0.00404	0.00404	CcSEcCtD
Apraclonidine—Skin disorder—Mitoxantrone—sarcoma	0.00404	0.00404	CcSEcCtD
Apraclonidine—Feeling abnormal—Thiotepa—sarcoma	0.00397	0.00397	CcSEcCtD
Apraclonidine—Feeling abnormal—Dactinomycin—sarcoma	0.00394	0.00394	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Thiotepa—sarcoma	0.00394	0.00394	CcSEcCtD
Apraclonidine—Ill-defined disorder—Etoposide—sarcoma	0.00393	0.00393	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dactinomycin—sarcoma	0.00391	0.00391	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Vincristine—sarcoma	0.00389	0.00389	CcSEcCtD
Apraclonidine—Insomnia—Vincristine—sarcoma	0.00386	0.00386	CcSEcCtD
Apraclonidine—Paraesthesia—Vincristine—sarcoma	0.00384	0.00384	CcSEcCtD
Apraclonidine—Malaise—Etoposide—sarcoma	0.00382	0.00382	CcSEcCtD
Apraclonidine—Face oedema—Epirubicin—sarcoma	0.00381	0.00381	CcSEcCtD
Apraclonidine—Abdominal pain—Thiotepa—sarcoma	0.00381	0.00381	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00379	0.00379	CcSEcCtD
Apraclonidine—Abdominal pain—Dactinomycin—sarcoma	0.00378	0.00378	CcSEcCtD
Apraclonidine—Paraesthesia—Mitoxantrone—sarcoma	0.00373	0.00373	CcSEcCtD
Apraclonidine—Dyspnoea—Mitoxantrone—sarcoma	0.00371	0.00371	CcSEcCtD
Apraclonidine—Somnolence—Mitoxantrone—sarcoma	0.0037	0.0037	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Vincristine—sarcoma	0.00369	0.00369	CcSEcCtD
Apraclonidine—Fatigue—Vincristine—sarcoma	0.00368	0.00368	CcSEcCtD
Apraclonidine—Constipation—Vincristine—sarcoma	0.00365	0.00365	CcSEcCtD
Apraclonidine—Pain—Vincristine—sarcoma	0.00365	0.00365	CcSEcCtD
Apraclonidine—Chest pain—Etoposide—sarcoma	0.00361	0.00361	CcSEcCtD
Apraclonidine—Fatigue—Mitoxantrone—sarcoma	0.00359	0.00359	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00358	0.00358	CcSEcCtD
Apraclonidine—Discomfort—Etoposide—sarcoma	0.00357	0.00357	CcSEcCtD
Apraclonidine—Pain—Mitoxantrone—sarcoma	0.00356	0.00356	CcSEcCtD
Apraclonidine—Constipation—Mitoxantrone—sarcoma	0.00356	0.00356	CcSEcCtD
Apraclonidine—Hypersensitivity—Thiotepa—sarcoma	0.00355	0.00355	CcSEcCtD
Apraclonidine—Nasopharyngitis—Epirubicin—sarcoma	0.00353	0.00353	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—sarcoma	0.00352	0.00352	CcSEcCtD
Apraclonidine—Hypersensitivity—Dactinomycin—sarcoma	0.00352	0.00352	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Vincristine—sarcoma	0.00349	0.00349	CcSEcCtD
Apraclonidine—Asthenia—Thiotepa—sarcoma	0.00346	0.00346	CcSEcCtD
Apraclonidine—Infection—Etoposide—sarcoma	0.00344	0.00344	CcSEcCtD
Apraclonidine—Asthenia—Dactinomycin—sarcoma	0.00343	0.00343	CcSEcCtD
Apraclonidine—Feeling abnormal—Mitoxantrone—sarcoma	0.00343	0.00343	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—sarcoma	0.00341	0.00341	CcSEcCtD
Apraclonidine—Pruritus—Thiotepa—sarcoma	0.00341	0.00341	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Mitoxantrone—sarcoma	0.0034	0.0034	CcSEcCtD
Apraclonidine—Abdominal pain—Vincristine—sarcoma	0.00338	0.00338	CcSEcCtD
Apraclonidine—Skin disorder—Etoposide—sarcoma	0.00336	0.00336	CcSEcCtD
Apraclonidine—Diarrhoea—Thiotepa—sarcoma	0.0033	0.0033	CcSEcCtD
Apraclonidine—Abdominal pain—Mitoxantrone—sarcoma	0.00329	0.00329	CcSEcCtD
Apraclonidine—Diarrhoea—Dactinomycin—sarcoma	0.00327	0.00327	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—sarcoma	0.00326	0.00326	CcSEcCtD
Apraclonidine—Dizziness—Thiotepa—sarcoma	0.00318	0.00318	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—sarcoma	0.00316	0.00316	CcSEcCtD
Apraclonidine—Hypersensitivity—Vincristine—sarcoma	0.00315	0.00315	CcSEcCtD
Apraclonidine—Paraesthesia—Etoposide—sarcoma	0.00311	0.00311	CcSEcCtD
Apraclonidine—Dyspnoea—Etoposide—sarcoma	0.00308	0.00308	CcSEcCtD
Apraclonidine—Somnolence—Etoposide—sarcoma	0.00308	0.00308	CcSEcCtD
Apraclonidine—Hypersensitivity—Mitoxantrone—sarcoma	0.00306	0.00306	CcSEcCtD
Apraclonidine—Asthenia—Vincristine—sarcoma	0.00306	0.00306	CcSEcCtD
Apraclonidine—Vomiting—Thiotepa—sarcoma	0.00306	0.00306	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—sarcoma	0.00304	0.00304	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—sarcoma	0.00304	0.00304	CcSEcCtD
Apraclonidine—Vomiting—Dactinomycin—sarcoma	0.00304	0.00304	CcSEcCtD
Apraclonidine—Dermatitis—Thiotepa—sarcoma	0.00303	0.00303	CcSEcCtD
Apraclonidine—Headache—Thiotepa—sarcoma	0.00302	0.00302	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Etoposide—sarcoma	0.00299	0.00299	CcSEcCtD
Apraclonidine—Asthenia—Mitoxantrone—sarcoma	0.00298	0.00298	CcSEcCtD
Apraclonidine—Fatigue—Etoposide—sarcoma	0.00298	0.00298	CcSEcCtD
Apraclonidine—Constipation—Etoposide—sarcoma	0.00296	0.00296	CcSEcCtD
Apraclonidine—Pain—Etoposide—sarcoma	0.00296	0.00296	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—sarcoma	0.00296	0.00296	CcSEcCtD
Apraclonidine—Diarrhoea—Vincristine—sarcoma	0.00292	0.00292	CcSEcCtD
Apraclonidine—Nausea—Thiotepa—sarcoma	0.00286	0.00286	CcSEcCtD
Apraclonidine—Feeling abnormal—Etoposide—sarcoma	0.00285	0.00285	CcSEcCtD
Apraclonidine—Diarrhoea—Mitoxantrone—sarcoma	0.00285	0.00285	CcSEcCtD
Apraclonidine—Nausea—Dactinomycin—sarcoma	0.00284	0.00284	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Etoposide—sarcoma	0.00283	0.00283	CcSEcCtD
Apraclonidine—Dizziness—Vincristine—sarcoma	0.00282	0.00282	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—sarcoma	0.00281	0.00281	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—sarcoma	0.00281	0.00281	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—sarcoma	0.00278	0.00278	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—sarcoma	0.00274	0.00274	CcSEcCtD
Apraclonidine—Abdominal pain—Etoposide—sarcoma	0.00273	0.00273	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—sarcoma	0.00273	0.00273	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—sarcoma	0.00273	0.00273	CcSEcCtD
Apraclonidine—Vomiting—Vincristine—sarcoma	0.00272	0.00272	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—sarcoma	0.00271	0.00271	CcSEcCtD
Apraclonidine—Dermatitis—Vincristine—sarcoma	0.00269	0.00269	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—sarcoma	0.00269	0.00269	CcSEcCtD
Apraclonidine—Headache—Vincristine—sarcoma	0.00268	0.00268	CcSEcCtD
Apraclonidine—Vomiting—Mitoxantrone—sarcoma	0.00264	0.00264	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—sarcoma	0.00263	0.00263	CcSEcCtD
Apraclonidine—Dermatitis—Mitoxantrone—sarcoma	0.00262	0.00262	CcSEcCtD
Apraclonidine—Headache—Mitoxantrone—sarcoma	0.00261	0.00261	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—sarcoma	0.00257	0.00257	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—sarcoma	0.00255	0.00255	CcSEcCtD
Apraclonidine—Hypersensitivity—Etoposide—sarcoma	0.00255	0.00255	CcSEcCtD
Apraclonidine—Nausea—Vincristine—sarcoma	0.00254	0.00254	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—sarcoma	0.00253	0.00253	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—sarcoma	0.00253	0.00253	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—sarcoma	0.00251	0.00251	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—sarcoma	0.00249	0.00249	CcSEcCtD
Apraclonidine—Asthenia—Etoposide—sarcoma	0.00248	0.00248	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—sarcoma	0.00248	0.00248	CcSEcCtD
Apraclonidine—Nausea—Mitoxantrone—sarcoma	0.00247	0.00247	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—sarcoma	0.00246	0.00246	CcSEcCtD
Apraclonidine—Pruritus—Etoposide—sarcoma	0.00245	0.00245	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—sarcoma	0.00244	0.00244	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—sarcoma	0.00243	0.00243	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—sarcoma	0.00239	0.00239	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—sarcoma	0.00238	0.00238	CcSEcCtD
Apraclonidine—Diarrhoea—Etoposide—sarcoma	0.00237	0.00237	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—sarcoma	0.00236	0.00236	CcSEcCtD
Apraclonidine—Tension—Epirubicin—sarcoma	0.00233	0.00233	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—sarcoma	0.00233	0.00233	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—sarcoma	0.00231	0.00231	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—sarcoma	0.00229	0.00229	CcSEcCtD
Apraclonidine—Dizziness—Etoposide—sarcoma	0.00229	0.00229	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—sarcoma	0.00228	0.00228	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—sarcoma	0.00226	0.00226	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—sarcoma	0.00224	0.00224	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—sarcoma	0.00221	0.00221	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—sarcoma	0.0022	0.0022	CcSEcCtD
Apraclonidine—Vomiting—Etoposide—sarcoma	0.0022	0.0022	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—sarcoma	0.0022	0.0022	CcSEcCtD
Apraclonidine—Dermatitis—Etoposide—sarcoma	0.00218	0.00218	CcSEcCtD
Apraclonidine—Headache—Etoposide—sarcoma	0.00217	0.00217	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—sarcoma	0.00216	0.00216	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—sarcoma	0.00215	0.00215	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—sarcoma	0.00214	0.00214	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—sarcoma	0.00214	0.00214	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—sarcoma	0.00213	0.00213	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—sarcoma	0.0021	0.0021	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—sarcoma	0.00207	0.00207	CcSEcCtD
Apraclonidine—Nausea—Etoposide—sarcoma	0.00206	0.00206	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—sarcoma	0.00204	0.00204	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—sarcoma	0.00202	0.00202	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—sarcoma	0.00202	0.00202	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00201	0.00201	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—sarcoma	0.002	0.002	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—sarcoma	0.00198	0.00198	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—sarcoma	0.00198	0.00198	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—sarcoma	0.00197	0.00197	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—sarcoma	0.00194	0.00194	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—sarcoma	0.00194	0.00194	CcSEcCtD
Apraclonidine—Infection—Epirubicin—sarcoma	0.00193	0.00193	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—sarcoma	0.0019	0.0019	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—sarcoma	0.00188	0.00188	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—sarcoma	0.00187	0.00187	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—sarcoma	0.00187	0.00187	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00186	0.00186	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—sarcoma	0.00185	0.00185	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—sarcoma	0.00183	0.00183	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—sarcoma	0.00179	0.00179	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—sarcoma	0.00178	0.00178	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—sarcoma	0.00177	0.00177	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—sarcoma	0.00176	0.00176	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—sarcoma	0.00175	0.00175	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—sarcoma	0.00174	0.00174	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—sarcoma	0.00174	0.00174	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—sarcoma	0.00173	0.00173	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—sarcoma	0.00172	0.00172	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—sarcoma	0.00167	0.00167	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—sarcoma	0.00167	0.00167	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—sarcoma	0.00166	0.00166	CcSEcCtD
Apraclonidine—Pain—Epirubicin—sarcoma	0.00166	0.00166	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.00163	0.00163	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—sarcoma	0.00162	0.00162	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—sarcoma	0.00161	0.00161	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—sarcoma	0.0016	0.0016	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—sarcoma	0.0016	0.0016	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—sarcoma	0.0016	0.0016	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—sarcoma	0.00159	0.00159	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00155	0.00155	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—sarcoma	0.00155	0.00155	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—sarcoma	0.00153	0.00153	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—sarcoma	0.00153	0.00153	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—sarcoma	0.00153	0.00153	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—sarcoma	0.00148	0.00148	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—sarcoma	0.00147	0.00147	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—sarcoma	0.00143	0.00143	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—sarcoma	0.00142	0.00142	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—sarcoma	0.00139	0.00139	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—sarcoma	0.00137	0.00137	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—sarcoma	0.00133	0.00133	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—sarcoma	0.00132	0.00132	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—sarcoma	0.00128	0.00128	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—sarcoma	0.00123	0.00123	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—sarcoma	0.00123	0.00123	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—sarcoma	0.00122	0.00122	CcSEcCtD
Apraclonidine—Headache—Epirubicin—sarcoma	0.00121	0.00121	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—sarcoma	0.00119	0.00119	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—sarcoma	0.00115	0.00115	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—sarcoma	0.00114	0.00114	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—sarcoma	0.00113	0.00113	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—sarcoma	0.00112	0.00112	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—sarcoma	0.00107	0.00107	CcSEcCtD
